If you have either of these, throw them out ASAP.
EDINBURGH, Scotland--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in ...
In May 2026, Dexcom disclosed FDA-enforced, Class II voluntary recalls of its G7 and ONE/ONE+ iOS and watchOS apps worldwide due to a software defect that can delay or replay glucose readings and ...
On the heels of the latest NICE guidelines, Dexcom ONE is in review by NHS England for addition to the Drug Tariff Dexcom ONE, a wearable sensor and transmitter, puts people firmly in control of their ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy ...
DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line. Which strategy stands out?
Dexcom has been abuzz this year amid the European approval—and submission for FDA approval in the U.S.—for its next-generation G7 continuous glucose monitoring system, which promises more accurate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results